Compare iShares China Large-Cap ETF (FXI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares China Large-Cap ETF vs Sana Biotechnology Inc — how do they compare? iShares China Large-Cap ETF trades at $35.22, while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). Which is the better fit depends on your goals.
| FXI | SANA | |
|---|---|---|
52-Week High | $41.75 | $5.92 |
52-Week Low | $31.59 | $2.68 |
Market Cap | — | $1.13B |
Sector | — | Health |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FXI trades at $35.23, down 3.45% on the day amid broader Chinese stock pressure. Technical indicators show a bullish overall signal with moving averages supporting upside momentum, while oscillators remain neutral. The ETF benefits from China's export strength and AI-driven manufacturing rebound, though financial ratios are currently unavailable. Recent news highlights China's 23% July export growth and ongoing infrastructure investments to support economic stability.
FXI offers exposure to China's large-cap recovery with state-backed stimulus and AI export growth as key catalysts. However, geopolitical tensions and US-China tech restrictions pose significant risks. The ETF's heavy financial sector weighting provides stability but limits pure tech exposure, requiring careful monitoring of China's economic policies and global trade dynamics.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares China Large-Cap ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
